VTGN

2.73

7.48% 0.19

Pre-mercato: 2.80 0.07 +2.56%

Vistagen Therapeutics Inc (VTGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.54

Aprire:

$2.661

Volume 24 ore:

110.26K

Relative Volume:

0.54

Capitalizzazione di mercato:

$79.60M

Reddito:

$875.70K

Utile/perdita netta:

$-39.57M

Rapporto P/E:

-2.0338

EPS:

-1.3423

Flusso di cassa netto:

$-33.65M

1 W Prestazione:

+10.53%

1M Prestazione:

+39.29%

6M Prestazione:

-8.08%

1 anno Prestazione:

-30.71%

Intervallo 1D:

$2.64

$2.7495

Intervallo di 1 settimana:

$2.40

$2.7495

Portata 52W:

$1.90

$3.94

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Nome

Vistagen Therapeutics Inc

Settore

Healthcare (1163)

Industria

Biotechnology (653)

Telefono

650-577-3600

Indirizzo

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Dipendente

Cinguettio

@vistagen

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

VTGN's Discussions on Twitter

Confronta VTGN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTGN Vistagen Therapeutics Inc	2.73	74.06M	875.70K	-39.57M	-33.65M	-1.3423
VRTX Vertex Pharmaceuticals Inc	476.95	120.73B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	572.39	60.56B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	325.64	42.41B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	575.42	34.96B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	294.83	31.99B	3.81B	-644.79M	-669.77M	-6.24

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-07	Aggiornamento	Jefferies	Hold → Buy
2023-08-07	Aggiornamento	Maxim Group	Hold → Buy
2022-07-22	Downgrade	Jefferies	Buy → Hold
2022-07-22	Downgrade	Robert W. Baird	Outperform → Neutral
2022-07-22	Downgrade	William Blair	Outperform → Mkt Perform
2021-05-20	Iniziato	Robert W. Baird	Outperform
2021-02-18	Iniziato	Jefferies	Buy
2021-01-04	Aggiornamento	William Blair	Mkt Perform → Outperform
2018-06-27	Iniziato	Maxim Group	Buy
2018-02-08	Reiterato	Chardan Capital Markets	Buy
2017-03-28	Iniziato	Maxim Group	Buy

Mostra tutto

Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie

Jul 23, 2025

What analysts say about Vistagen Therapeutics Inc. stockExceptional earning trajectories - Autocar Professional

Jul 23, 2025

Is Vistagen Therapeutics Inc. a good long term investmentTremendous financial leverage - jammulinksnews.com

Jul 23, 2025

What drives Vistagen Therapeutics Inc. stock priceHigh-velocity capital appreciation - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Vistagen Therapeutics Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com

Jul 22, 2025

What makes Vistagen Therapeutics Inc. stock price move sharply2x Return Forecast - Newser

Jul 22, 2025

Jul 19, 2025

VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50-Day Moving AverageHere's Why - MarketBeat

Jul 19, 2025

Jul 18, 2025

Is Vistagen Therapeutics Inc. stock a good hedge against inflationHigh Confidence Trade Setups - beatles.ru

Jul 18, 2025

Jul 15, 2025

How Vistagen Therapeutics Inc. stock performs during market volatilityEntry Level Low Risk Picks - Newser

Jul 15, 2025

Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser

Jul 15, 2025

Biotech Leader Vistagen Achieves Rare Double Honor: Mental Health Excellence and Workplace Culture Awards - Stock Titan

Jul 15, 2025

Jul 13, 2025

Mental Disorder Treatment Market CAGR 28.16% key trends with - openPR.com

Jul 13, 2025

Jul 11, 2025

Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay - MSN

Jul 11, 2025

Jun 26, 2025

15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey

Jun 26, 2025

Jun 25, 2025

Vistagen appoints Elissa Cote as Chief Corporate Development Officer By Investing.com - Investing.com Nigeria

Jun 25, 2025

Vistagen (VTGN) Appoints Elissa Cote as Chief Corporate Development Officer | VTGN Stock News - GuruFocus

Jun 25, 2025

Vistagen appoints Elissa Cote as Chief Corporate Development Officer - Investing.com

Jun 25, 2025

Jun 23, 2025

William Blair Issues Negative Forecast for VTGN Earnings - Defense World

Jun 23, 2025

Jun 22, 2025

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript - Insider Monkey

Jun 22, 2025

Jun 21, 2025

William Blair Reiterates Outperform Rating for VistaGen Therapeutics (NASDAQ:VTGN) - MarketBeat

Jun 21, 2025

Jun 20, 2025

Vistagen Therapeutics (VTGN): Can Fasedienol's Phase 3 Success Overcome Financial Strains? - AInvest

Jun 20, 2025

Jun 19, 2025

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Jun 19, 2025

VistaGen Therapeutics (NASDAQ:VTGN) Receives Outperform Rating from William Blair - Defense World

Jun 19, 2025

Jun 18, 2025

Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada

Jun 18, 2025

Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus

Jun 18, 2025